by Jonathan N. Hofmann, Linda M. Liao, Michael N

Slides:

Advertisements

Similar presentations

What is the role of free PSA? Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years) %Free PSA=60 (yrs)All Ages

Advertisements

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Alternate designs for conduct and analysis of phase I cancer trials

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.

How I treat multiple myeloma in younger patients

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

بهداشت فردي.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Finding a diamond in the (mouse is) rough

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

by Morgan Craig, Antony R. Humphries, and Michael C. Mackey

A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation by Chunfu.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

by Nataliya Melnyk, and Jonathan Harrison

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Solid cancers after allogeneic hematopoietic cell transplantation

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients by Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla,

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective.

Genetic sequence analysis of inherited bleeding diseases

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping by David C. Johnson, Sophie Corthals,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the Study of Women's Health Across the Nation Rebecca C.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

by Adetola A. Kassim, Amanda B. Payne, Mark Rodeghier, Eric A

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Hepatitis C infection among survivors of childhood cancer

Has MRD monitoring superseded other prognostic factors in adult ALL?

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

Volume 55, Issue 3, Pages (March 2009)

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Volume 2(Supplement 1):1-3

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,

Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes by Richard D Neal, Victoria L Allgar,

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.

Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Cancer-associated pathways and biomarkers of venous thrombosis

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

A prospective study of circulating adipokine levels and risk of multiple myeloma by Jonathan N. Hofmann, Linda M. Liao, Michael N. Pollak, Ye Wang, Ruth M. Pfeiffer, Dalsu Baris, Gabriella Andreotti, Qing Lan, Ola Landgren, Nathaniel Rothman, and Mark P. Purdue Blood Volume 120(22):4418-4420 November 22, 2012 ©2012 by American Society of Hematology

Risk of MM in relation to prediagnostic circulating levels of total adiponectin, HMW adiponectin, and leptin in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Risk of MM in relation to prediagnostic circulating levels of total adiponectin, HMW adiponectin, and leptin in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Jonathan N. Hofmann et al. Blood 2012;120:4418-4420 ©2012 by American Society of Hematology